Norethindrone Acetate side effects: what 1,655 FDA adverse event reports show
Who reports
1,655 reports · 40% serious · 24 with death outcome · 99% female
Used for
1. Indications Progestin-only oral contraceptives are indicated for the prevention of pregnancy. 2. Efficacy If used perfectly, the first-year failure rate for progestin-only oral contraceptives is 0.3%. However, the typical failure rate is estimated to be closer to 9%, due to late or omitted pills. Table 1 lists the pregnancy rates for users of all major methods of contraception.
Boxed warning
None in the current label
Causality screen of the 30 strongest signals
What the badges mean
- Labeled adverse reaction The exact term appears in the label's warnings or adverse-reactions sections: a known, expected effect. The FAERS signal confirms the label rather than discovering anything.
- Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
- Likely indication confounding The term appears in the label's indications: reports probably describe the disease being treated (or its progression), not a drug effect. Classic confounding by indication.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only and flags pairs whose reports are unusually skewed by sex or come mostly from consumers rather than clinicians. 32 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Pelvic pain | 127 | 89.1 75.3–105.3ROR 96.4 · χ² 10,903 / p <1e-300 | 87.3 EB05 75.3 · IC025 +5.7 3/3 methods agree | Not in label — unassessed | serious PRR 72.1 · 83% consumer | no trial data cached |
| Menorrhagia (heavy periods) | 99 | 63.3 52.2–76.6ROR 67.2 · χ² 5,980 / p <1e-300 | 62.2 EB05 52.6 · IC025 +5.3 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 55.0 · 79% consumer | no trial data cached |
| Metrorrhagia | 67 | 49.3 38.9–62.3ROR 51.3 · χ² 3,111 / p <1e-300 | 48.4 EB05 39.5 · IC025 +4.8 3/3 methods agree | Not in label — unassessed | serious n=10 · 88% consumer | no trial data cached |
| Dysmenorrhoea | 44 | 42.8 31.9–57.3ROR 43.9 · χ² 1,748 / p <1e-300 | 41.9 EB05 32.5 · IC025 +4.4 3/3 methods agree | Not in label — unassessed | serious n=14 · 84% consumer | no trial data cached |
| Hot flush (hot flashes) | 210 | 35.4 31.2–40.2ROR 40.4 · χ² 6,989 / p <1e-300 | 35.2 EB05 31.4 · IC025 +4.8 3/3 methods agree | Not in label — unassessed | serious PRR 32.3 · 88% consumer | no trial data cached |
| Vaginal haemorrhage | 118 | 35.2 29.6–41.9ROR 37.8 · χ² 3,885 / p <1e-300 | 34.9 EB05 30.0 · IC025 +4.6 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 25.0 · 83% consumer | no trial data cached |
| Mood swings | 84 | 33.4 27.1–41.2ROR 35.2 · χ² 2,609 / p <1e-300 | 33.1 EB05 27.6 · IC025 +4.4 3/3 methods agree | Not in label — unassessed | serious PRR 22.8 · 89% consumer | no trial data cached |
| Ovarian cyst | 21 | 26.5 17.3–40.6ROR 26.8 · χ² 489 / p 9e-109 | 25.9 EB05 17.8 · IC025 +3.3 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 37.7 | no trial data cached |
| Night sweats | 49 | 19.3 14.7–25.4ROR 19.9 · χ² 832 / p 2e-183 | 19.1 EB05 15.0 · IC025 +3.5 3/3 methods agree | Not in label — unassessed | serious PRR 11.5 · 92% consumer | no trial data cached |
| Vaginal discharge | 15 | 18.9 11.4–31.4ROR 19.1 · χ² 237 / p 9e-54 | 18.3 EB05 11.4 · IC025 +2.7 3/3 methods agree | Labeled (related wording) related wording | serious n=3 | no trial data cached |
| Breast cancer metastatic | 15 | 17.7 10.7–29.4ROR 17.9 · χ² 220 / p 4e-50 | 17.0 EB05 10.5 · IC025 +2.7 3/3 methods agree | Not in label — unassessed | serious PRR 25.7 | no trial data cached |
| Menstruation irregular | 35 | 16.7 12.1–23.2ROR 17.1 · χ² 502 / p 2e-111 | 16.5 EB05 12.3 · IC025 +3.2 3/3 methods agree | Labeled (related wording) related wording | serious n=9 · 89% consumer | no trial data cached |
| Libido decreased (lower sex drive) | 12 | 12.3 7.0–21.6ROR 12.4 · χ² 113 / p 9e-27 | 10.6 EB05 5.8 · IC025 +2.1 3/3 methods agree | Not in label — unassessed | serious PRR 10.3 | no trial data cached |
| Mood altered | 26 | 12.1 8.3–17.8ROR 12.3 · χ² 255 / p 1e-57 | 11.5 EB05 7.9 · IC025 +2.7 3/3 methods agree | Not in label — unassessed | serious PRR 4.7 · 77% consumer | no trial data cached |
| Breast pain | 10 | 11.9 6.4–22.1ROR 12.0 · χ² 89 / p 2e-21 | 9.8 EB05 5.0 · IC025 +1.9 3/3 methods agree | Labeled adverse reaction exact term | serious n=4 | no trial data cached |
| Migraine | 81 | 10.8 8.8–13.4ROR 11.3 · χ² 715 / p 7e-158 | 10.6 EB05 8.7 · IC025 +3.0 3/3 methods agree | Not in label — unassessed | serious PRR 7.4 · 82% consumer | no trial data cached |
| Amenorrhoea (missed periods) | 13 | 9.9 5.7–17.0ROR 9.9 · χ² 95 / p 1e-22 | 8.3 EB05 4.8 · IC025 +2.0 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious PRR 9.9 | no trial data cached |
| Acute hepatic failure | 10 | 9.3 5.0–17.3ROR 9.4 · χ² 66 / p 2e-16 | 7.3 EB05 4.0 · IC025 +1.7 3/3 methods agree | Not in label — unassessed | serious PRR 13.3 | no trial data cached |
| Breast cancer | 67 | 9.0 7.1–11.4ROR 9.4 · χ² 472 / p 5e-105 | 8.7 EB05 7.0 · IC025 +2.7 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 12.9 · 87% consumer | no trial data cached |
| Abdominal pain lower | 17 | 8.5 5.3–13.6ROR 8.6 · χ² 105 / p 6e-25 | 7.3 EB05 4.7 · IC025 +2.0 3/3 methods agree | Labeled (related wording) related wording | serious PRR 10.7 | no trial data cached |
| Crying | 24 | 8.3 5.6–12.4ROR 8.4 · χ² 148 / p 2e-34 | 7.5 EB05 5.2 · IC025 +2.2 3/3 methods agree | Not in label — unassessed | serious PRR 4.2 · 71% consumer | no trial data cached |
| Feeling jittery | 12 | 8.0 4.5–14.0ROR 8.0 · χ² 66 / p 2e-16 | 6.5 EB05 3.8 · IC025 +1.7 3/3 methods agree | Not in label — unassessed | serious n=3 | no trial data cached |
| Middle insomnia | 10 | 6.8 3.7–12.6ROR 6.8 · χ² 44 / p 2e-11 | 5.4 EB05 3.1 · IC025 +1.3 3/3 methods agree | Not in label — unassessed | serious PRR 12.7 | no trial data cached |
| Panic attack | 14 | 4.9 2.9–8.2ROR 4.9 · χ² 39 / p 2e-10 | 4.2 EB05 2.7 · IC025 +1.2 3/3 methods agree | Not in label — unassessed | serious PRR 5.0 | no trial data cached |
| Emotional disorder | 11 | 4.5 2.5–8.1ROR 4.5 · χ² 27 / p 1e-7 | 3.9 EB05 2.3 · IC025 +0.9 3/3 methods agree | Not in label — unassessed | serious PRR 1.1 | no trial data cached |
| Anger | 12 | 4.5 2.5–7.9ROR 4.5 · χ² 29 / p 4e-8 | 3.9 EB05 2.4 · IC025 +1.0 3/3 methods agree | Not in label — unassessed | serious PRR 4.4 | no trial data cached |
| Acne | 23 | 3.8 2.5–5.7ROR 3.9 · χ² 45 / p 8e-12 | 3.6 EB05 2.5 · IC025 +1.2 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 7.0 · 74% consumer | no trial data cached |
| Suicidal ideation (thoughts of suicide) | 23 | 3.2 2.1–4.8ROR 3.2 · χ² 32 / p 6e-9 | 3.0 EB05 2.1 · IC025 +0.9 3/3 methods agree | Not in label — unassessed | serious PRR 3.9 | no trial data cached |
| Dermatitis atopic | 10 | 2.5 1.4–4.7ROR 2.5 · χ² 8 / p 0.003 | 2.4 EB05 1.4 · IC025 +0.2 | Not in label — unassessed | – | no trial data cached |
| Injection site pain (pain where injected) | 49 | 2.0 1.6–2.7ROR 2.1 · χ² 26 / p 2e-7 | 2.0 EB05 1.6 · IC025 +0.5 | Labeled (related wording) related wording | serious PRR 3.8 · 86% consumer | no trial data cached |
Trial evidence (ClinicalTrials.gov)
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Hot flush (hot flashes) | 210 | 35.4 31.2–40.2ROR 40.4 · χ² 6,989 / p <1e-300 | 35.2 EB05 31.4 · IC025 +4.8 3/3 methods agree | Not in label — unassessed | serious PRR 32.3 · 88% consumer | no trial data cached |
| Pelvic pain | 127 | 89.1 75.3–105.3ROR 96.4 · χ² 10,903 / p <1e-300 | 87.3 EB05 75.3 · IC025 +5.7 3/3 methods agree | Not in label — unassessed | serious PRR 72.1 · 83% consumer | no trial data cached |
| Vaginal haemorrhage | 118 | 35.2 29.6–41.9ROR 37.8 · χ² 3,885 / p <1e-300 | 34.9 EB05 30.0 · IC025 +4.6 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 25.0 · 83% consumer | no trial data cached |
| Menorrhagia (heavy periods) | 99 | 63.3 52.2–76.6ROR 67.2 · χ² 5,980 / p <1e-300 | 62.2 EB05 52.6 · IC025 +5.3 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 55.0 · 79% consumer | no trial data cached |
| Mood swings | 84 | 33.4 27.1–41.2ROR 35.2 · χ² 2,609 / p <1e-300 | 33.1 EB05 27.6 · IC025 +4.4 3/3 methods agree | Not in label — unassessed | serious PRR 22.8 · 89% consumer | no trial data cached |
| Migraine | 81 | 10.8 8.8–13.4ROR 11.3 · χ² 715 / p 7e-158 | 10.6 EB05 8.7 · IC025 +3.0 3/3 methods agree | Not in label — unassessed | serious PRR 7.4 · 82% consumer | no trial data cached |
| Breast cancer | 67 | 9.0 7.1–11.4ROR 9.4 · χ² 472 / p 5e-105 | 8.7 EB05 7.0 · IC025 +2.7 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 12.9 · 87% consumer | no trial data cached |
| Metrorrhagia | 67 | 49.3 38.9–62.3ROR 51.3 · χ² 3,111 / p <1e-300 | 48.4 EB05 39.5 · IC025 +4.8 3/3 methods agree | Not in label — unassessed | serious n=10 · 88% consumer | no trial data cached |
| Injection site pain (pain where injected) | 49 | 2.0 1.6–2.7ROR 2.1 · χ² 26 / p 2e-7 | 2.0 EB05 1.6 · IC025 +0.5 | Labeled (related wording) related wording | serious PRR 3.8 · 86% consumer | no trial data cached |
| Night sweats | 49 | 19.3 14.7–25.4ROR 19.9 · χ² 832 / p 2e-183 | 19.1 EB05 15.0 · IC025 +3.5 3/3 methods agree | Not in label — unassessed | serious PRR 11.5 · 92% consumer | no trial data cached |
| Dysmenorrhoea | 44 | 42.8 31.9–57.3ROR 43.9 · χ² 1,748 / p <1e-300 | 41.9 EB05 32.5 · IC025 +4.4 3/3 methods agree | Not in label — unassessed | serious n=14 · 84% consumer | no trial data cached |
| Menstruation irregular | 35 | 16.7 12.1–23.2ROR 17.1 · χ² 502 / p 2e-111 | 16.5 EB05 12.3 · IC025 +3.2 3/3 methods agree | Labeled (related wording) related wording | serious n=9 · 89% consumer | no trial data cached |
| Mood altered | 26 | 12.1 8.3–17.8ROR 12.3 · χ² 255 / p 1e-57 | 11.5 EB05 7.9 · IC025 +2.7 3/3 methods agree | Not in label — unassessed | serious PRR 4.7 · 77% consumer | no trial data cached |
| Crying | 24 | 8.3 5.6–12.4ROR 8.4 · χ² 148 / p 2e-34 | 7.5 EB05 5.2 · IC025 +2.2 3/3 methods agree | Not in label — unassessed | serious PRR 4.2 · 71% consumer | no trial data cached |
| Suicidal ideation (thoughts of suicide) | 23 | 3.2 2.1–4.8ROR 3.2 · χ² 32 / p 6e-9 | 3.0 EB05 2.1 · IC025 +0.9 3/3 methods agree | Not in label — unassessed | serious PRR 3.9 | no trial data cached |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Pelvic pain — n=127, PRR 89.1
- Metrorrhagia — n=67, PRR 49.3
- Dysmenorrhoea — n=44, PRR 42.8
- Hot flush — n=210, PRR 35.4
- Mood swings — n=84, PRR 33.4
- Night sweats — n=49, PRR 19.3
- Mood altered — n=26, PRR 12.1
- Migraine — n=81, PRR 10.8
- Crying — n=24, PRR 8.3
- Suicidal ideation — n=23, PRR 3.2
✓ A hand-written Bradford Hill causality assessment exists for this drug: Medroxyprogesterone acetate ↔ Meningioma.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Norethindrone?
In FDA FAERS, the most frequently co-reported reaction terms for Norethindrone are hot flush, pelvic pain, vaginal haemorrhage, menorrhagia, mood swings, migraine. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Norethindrone have an FDA boxed warning?
No. The FDA label retrieved for Norethindrone has no boxed warning; see the label's Warnings and Precautions for the recognised risks.
Do FAERS signals prove that Norethindrone causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 0d2f8fea-3675-40d2-afd9-9fcb148dbd4b, effective 20260131; matched on
openfda.generic_name.exact:"NORETHINDRONE") - Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 62 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath
Page generated 2026-10-08. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.